• Lung
    Categories: , ,

    MSD’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression

    17 Mar 2022

  • Melanoma
    Categories: , ,

    PRESS RELEASE: European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients

    29 Jun 2021

  • Breast cancer study - Ameera-study_EORTC-Sanofi-BIG-AFT
    Categories: , ,

    PRESS RELEASE: Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer

    4 Jun 2021

  • HRH Princess Dina Mired - ECRF & EORTC Honorary President
    Categories: ,

    PRESS RELEASE: HSH Prince Albert II cedes Honorary Presidency of the EORTC Research Fund to HRH Princess Dina Mired

    20 Apr 2021

  • SISAQOL press release - illustration
    Categories: , ,

    PRESS RELEASE: Generating recommendations for the design, analysis and interpretation of patient- reported outcome (PRO) data for cancer clinical trials: the launch of SISAQOL-IMI

    17 Feb 2021

  • EORTC 1945 OligoRARE trial
    Categories: ,

    PRESS RELEASE: EORTC 1945 OligoRARE trial in oligometastatic rare cancers receives support by Anticancer Fund & Rising Tide Foundation

    2 Feb 2021

  • lung-x-ray
    Categories: , ,

    PRESS RELEASE: First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Study

    20 Jan 2021

  • A. Eggermont - ESMO 2020
    Categories: , ,

    PRESS RELEASE: KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Compared Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma

    19 Sep 2020